In August 2011, we recorded a podcast around our ALN-VSP program for the treatment of liver cancers. The discussion was led by our own Jared Gollob, M.D., Senior Director of Clinical Research, and Dr. Geoffrey Shapiro, M.D., Ph.D. of the Dana Farber Cancer Institute.
Listen to podcast discussing ALN-VSP and future of Phase I oncology trials (37.6MB MP3) Read our press release ALN-VSP Ph1 ClinicalStudyResults-ASCO2011 (1.2MB PPT)Posts Tagged with: Liver Cancers
June 29, 2011
ALN-VSP Data at 2011 ASCO Meeting
At the ASCO Annual Meeting in June 2011, we presented complete results from our Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of patients with advanced solid tumors with liver involvement.
Read our press release ALN-VSP PhI ClinicalStudyResults-ASCO2011 (1.2MB PPT) ALN-VSP RNAi Roundtable, May 2011 (2.2 MB PPT) Listen to Dr. Jared Gollob discuss ALN-VSP data at ASCO 2011 (3.1MB MP3)May 31, 2011
Alnylam RNAi Roundtable: ALN-VSP Proof of Mechanism Data
In May 2011, we held a roundtable discussion focused on our ALN-VSP program; specifically, the important proof of mechanism data that we had reported on earlier in the year.
ALN-VSP RNAi Roundtable webcast, May 2011 (65 MB MP3) ALN-VSP RNAi Roundtable, May 2011 (2.2 MB PPT) Read our press releaseJanuary 4, 2011
RNAi in Man: Initial Results from ALN-VSP Phase I Clinical Trial
In January 2011, Jared Gollob, M.D., Senior Director of Clinical Research at Alnylam, presented important clinical data from our ALN-VSP Phase I trial, demonstrating that RNAi can be harnessed in man using systemically delivered RNAi therapeutics.
Read our press release Dana Farber ALN-VSP Proof of Mechanism